This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Sumitomo Dainippon Pharma Co., Ltd.. Active years: 2018.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2018
Title: Yuka Kato: Innovator in Ophthalmic Formulations
Introduction
Yuka Kato is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of ophthalmology through his innovative formulations. His work focuses on developing solutions that enhance the treatment of eye diseases while minimizing side effects.
Latest Patents
Yuka Kato holds a patent for an ophthalmic suspension formulation. This formulation comprises (R)-(−)-2-(4-bromo-2-fluorobenzyl)-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-4-spiro-3'-pyrrolidine-1,2′,3,5′-tetrone. It is particularly useful for treating diseases in the posterior eye segment, effectively avoiding systemic exposure and its associated side effects. He has 1 patent to his name.
Career Highlights
Yuka Kato is associated with Sumitomo Dainippon Pharma Co., Ltd., where he continues to push the boundaries of pharmaceutical innovation. His dedication to research and development has positioned him as a key player in the industry.
Collaborations
Yuka collaborates with talented professionals in his field, including Yasushi Ochiai and Maki Sasaki. Their combined expertise fosters an environment of innovation and progress in ophthalmic research.
Conclusion
Yuka Kato's contributions to ophthalmic formulations exemplify the impact of innovative thinking in medicine. His work not only advances treatment options but also prioritizes patient safety.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile